Earlier this year, Orum Therapeutics moved to a bigger office and lab location in Daejeon. We are now excited to announce our international expansion into Boston.
“We evaluated multiple locations in the United States and determined that Boston’s depth of expertise and experience in drug development matched what Orum needs to advance our unique cell-penetrating antibodies,” said Sung Joo Lee, Ph.D., Orum’s founder and CEO. “We look forward to joining the strong biotech ecosystem in Massachusetts and working with talented individuals who are passionate about bringing new medicines to patients with life-threatening illnesses.”
Orum Therapeutics is developing a new class of therapeutic antibodies to target previously undruggable proteins that are involved in aggressive cancers and severe genetic diseases. The company’s unique cell-penetrating antibody platform can be readily adapted to target specific cell types and inhibit different intracellular targets, without chemical modification. The company has a pipeline of preclinical therapeutic candidates, of which the most advanced targets oncogenic Ras proteins.
As we prepare to open our Boston location, we are on the lookout for outstanding researchers who are passionate about developing antibody therapeutics against undruggable targets to join our U.S. team.